<DOC>
	<DOCNO>NCT00013689</DOCNO>
	<brief_summary>This study evaluate safety effectiveness antibiotic call Fansidar autoimmune lymphoproliferative syndrome ( ALPS ) . Patients ALPS enlarge lymph gland , spleen and/or liver , abnormal blood cell count overactive immune function . Current treatment aim suppress immune system improve symptom , anemia ( low red blood cell count ) low white blood cell platelet count . These treatment , however , partially effective may complication . Fansidar combination two drug , sulfadoxine pyrimethamine , use treat prevent parasitic infection malaria . Recently child ALPS treat Fansidar different illness mark shrinkage lymph organ . This study examine whether Fansidar shrink lymph gland spleen patient ALPS . Patients ALPS age 4 70 year lymph gland enlargement least 1 year allergic sulfa drug may eligible study . Candidates screen medical history physical examination blood test . Females reproductive age urine pregnancy test . Participants evaluate NIH Clinical Center Bethesda , MD , blood test compute tomography ( CT ) scan lymph node . For CT scan , patient lie table X-ray scan neck , part chest , , spleen remove , stomach area . When baseline test complete , patient give Fansidar pill take week 12 week . The dosage increase 2 week 4 week . At 2 , 4 , 6 , 8 10 week start treatment 2 week last dose , patient blood draw check possible side effect therapy . Women repeat urine pregnancy test week 6 treatment . Within week complete treatment complete treatment , patient return NIH history , physical examination , blood test CT scan . Patients respond well treatment offer return NIH 3 , 6 12 month later repeat evaluation . If ALPS symptoms recur time , patient offer another 12-week course Fansidar procedure , include 3 , 6 12-month evaluation repeat . If symptoms recur , patient ask resume Fansidar 6 month longer , dos adjust need . During time , patient see NIH every 12 week evaluation blood drawn patient 's private physician every 6 week 2 4 week dose increase check side effect .</brief_summary>
	<brief_title>Pyrimethamine Sulfadoxine Treatment Autoimmune Lymphoproliferative Syndrome</brief_title>
	<detailed_description>The Autoimmune Lymphoproliferative Syndrome inherit disease associate defect lymphocyte apoptosis , lymphoproliferation autoimmunity . Although , treatment many autoimmune complication , currently safe effective therapy syndrome . Recently investigator Europe serendipitously find child ALPS type I significant clinical improvement pyrimethamine/sulfadoxine ( Fansidar ) Pneumocystis carinii prophylaxis . Based finding , propose conduct pilot study obtain information safety initial data efficacy drug combination Fansidar treatment ALPS . Six 8 individual , ALPS report allergy sulfa drug treat 3 month weekly Fansidar escalating dos adjust weight . The effect Fansidar treatment lymph node and/or spleen size assess CT scan . The effect treatment laboratory feature ALPS also assess . Evaluating effect Fansidar clinical laboratory parameter allow u determine drug demonstrate sufficient activity warrant study large randomize control trial .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>INCLUSION CRITERIA All subject must fulfill current criterion diagnosis ALPS ( document nonmalignant lymphadenopathy and/or splenomegaly least 1 year duration ; great equal 1 % TCR alpha/beta ( + ) CD4 ( ) CD8 ( ) T cell peripheral blood defective apoptosis vitro assay ) . Subjects must 4 70 year age . Subjects must primary care physician . EXCLUSION CRITERIA Weigh le 18 kg ( 40 lb . ) exclude . Have know hypersensitivity reaction pyrimethamine , sulfonamide , sulfonylurea , furosemide sulfalike drug exclude . If receive require antifolate drug sulfonamide , trimethoprim , pyrimethamine methotrexate exclude . Patients G6PD deficient exclude . Have history megaloblastic anemia , folate deficiency mean corpuscular volume great 101 CU MICR exclude . Have usual Hb concentration le 9 gm/dl , platelet count le 75 K/mm ( 3 ) , absolute neutrophil count le 1000/mm ( 3 ) exclude . Liver disease determine ALT , AST bilirubin 3 time upper limit normal , and/or serum albumin le 3 gm/dL exclude . Renal dysfunction determine calculated creatinine clearance less equal 70 ml/min/1.73 ( 2 ) child less equal 60 ml/min adult exclude . Patients immunosuppression ( eg : corticosteroid , azathioprine , cyclophosphamide , etc . ) eligible dose immunosuppressive drug stable least 6 month prior enrollment exclude . Pregnant woman exclude . Women reproductive age must negative pregnancy test commit use acceptable method contraception . Unwilling unable comply need periodic blood test monitor possible side effect treatment , major requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Lymphadenopathy</keyword>
	<keyword>Splenomegaly</keyword>
	<keyword>Children</keyword>
	<keyword>Tomography</keyword>
	<keyword>Autoimmune Lymphoproliferative Syndrome ( ALPS )</keyword>
</DOC>